Micron (MU) traded up 2.46 % during a 24 hours period ending at 11:22 PM Central Europe on Monday 26th. One Micron stock can currently be bought for about USD 903.7 on popular exchanges. Current supply of Micron stocks is 1.1 bn. Micron has a current market capitalization of USD 992.9 bn and approximately USD 18.6 bn worth of Micron was traded on exchanges in the last 24 hours. Since last month end, Micron has traded -18.79 % down. Simple moving average of last 200 days is at USD 732.1. The highest price of past 52 weeks was recorded at USD 1,255 on 06/25/2026. 52 weeks low was at USD 192.59 on 11/21/2025.
Summary of the latest news for Micron
Micron Technology Inc. has seen its stock trade within a narrow range during the day, reflecting a steady but modest performance amid broader market volatility. The semiconductor company’s shares remained largely stable, with limited movement that suggests investors are monitoring ongoing supply‑chain dynamics and the company’s recent product developments. No significant corporate announcements or earnings releases were reported in the period covered, and the broader sector has experienced mixed results, with some memory‑chip peers posting gains while others see modest declines. The overall market context includes continued interest in AI‑related hardware, but the immediate impact on Micron’s valuation appears neutral.
Here is how related stocks have performed in the past 24 hours:
Mastercard (MA) traded down -1.52 % and now trades at USD 613.59. Current market capitalisation for Mastercard is USD 546.3 bn. Mastercard has a current price to earnings ratio of 34.21. Mastercard Inc. reported its earnings for the quarter, noting continued investment in artificial‑intelligence initiatives while acknowledging cash outflows that surpassed inflows. The company also announced a two‑for‑one share split and the issuance of non‑voting shares to support further expansion. These developments come amid a broader earnings season that includes other major technology names such as Amazon, Microsoft, and Alphabet. Investors are also watching the Federal Reserve’s upcoming policy decision, as market participants assess the potential impact of interest‑rate levels on consumer spending and corporate investment. The overall market environment remains volatile, with recent oil price movements adding additional pressure to equity valuations, while bond yields have shown signs of a re‑emerging hedge function. Mastercard’s financial update reflects a cautious approach to growth investments amid uncertain macro‑economic conditions.
Berkshire Hathaway (BKHT) traded flat 0 % and now trades at USD 392,434.27. Berkshire Hathaway has a market capitalisation of USD 1.2 trillions. Berkshire Hathaway has a current price to earnings ratio of 13.61. Berkshire Hathaway’s rail subsidiary, Railserve, has announced the integration of advanced artificial‑intelligence sensing technology from Rail Vision into its YardGUARD safety platform. The partnership combines Rail Vision’s multispectral perception system with Railserve’s existing shunting operations, enabling earlier detection of hazards and supporting personnel during yard movements. By embedding these capabilities into a commercial safety suite, the company aims to reduce disruptions and enhance operational continuity on industrial rail sites across North America. Early commercial deployment has already led to increased customer engagements, and the collaboration is expected to drive further adoption as the technology proves its value in real‑world rail yard environments.
Johnson & Johnson (JNJ) traded down -1.42 % and now trades at USD 266.3. Current market capitalisation for Johnson & Johnson is USD 635.1 bn. Current price/earnings ratio for Johnson & Johnson is 29.18. Johnson & Johnson reported encouraging early results for two investigational oncology therapies. In prostate cancer, the once‑daily RIPTAC compound JNJ‑6143 achieved a 75‑percent tumor response rate in a small, heavily pretreated cohort, with most responders maintaining disease control over a six‑month follow‑up. PSA reductions were also notable, with a majority of patients experiencing at least a 50‑percent decline. Safety signals were mild to moderate, and the 50‑mg dose was chosen for further study. In head‑and‑neck cancer, the subcutaneous bispecific antibody RYBREVANT FASPRO, combined with a PD‑1 inhibitor and limited‑duration carboplatin, produced a 77‑percent overall response rate in non‑HPV‑associated cases, and most responses persisted at a median 10‑month follow‑up. The therapy also showed durable overall survival at one year in this subgroup. Both programs are advancing to pivotal trials, with RYBREVANT FASPRO entering a Phase 3 study and JNJ‑6143 progressing to Phase 2 development.
Advanced Micro Devices (AMD) traded up 1.74 % and now trades at USD 531.28. Current market capitalisation for Advanced Micro Devices is USD 843.7 bn. Advanced Micro Devices has a current price to earnings ratio of 132.16. Advanced Micro Devices reported a modest improvement in its recent earnings performance, reflecting stronger demand for its semiconductor products. Company executives highlighted a gradual uptick in revenue driven by continued customer adoption across key market segments, including data centers and automotive applications. Management noted that operating margins have remained stable, thanks to disciplined cost control and efficient supply‑chain management. The firm also reaffirmed its commitment to investing in research and development, underscoring ongoing efforts to expand its product portfolio and maintain a competitive edge. Analysts observed that the company’s guidance for the next quarter indicates a steady trajectory, with no immediate catalysts for significant volatility. Overall, the update portrays a company maintaining solid fundamentals while pursuing incremental growth and innovation.
Eli Lilly & (LLY) traded down -2.54 % and now trades at USD 1,279.14. Current market capitalisation for Eli Lilly & is USD 1.1 trillions. Eli Lilly & has a current price to earnings ratio of 42.58. Eli Lilly announced new first‑line data for its investigational KRAS G12C inhibitor, olomorasib, at the 2026 ESMO Congress. Results from a phase 1/2 study and the safety‑lead‑in portion of a phase 3 trial showed durable activity when combined with the PD‑1 inhibitor pembrolizumab, with neither median progression‑free survival nor response duration reached after roughly 21 months of follow‑up. In a separate single‑arm analysis of olomorasib plus chemo‑immunotherapy, the investigator‑assessed overall response rate was about 62 %, with a median response duration around 14½ months and a median progression‑free survival near 11½ months. Adverse events were manageable, with no fatal treatment‑related events reported. Lilly expects the first randomized phase 3 SUNRAY‑01 results in the first half of 2027, which will further evaluate olomorasib in combination with immunotherapy, with or without chemotherapy, across all PD‑L1 expression levels.
About Micron
Micron Technology Inc., through its subsidiaries, specializes in manufacturing and marketing dynamic random access memory chips (DRAMs), static random access memory chips (SRAMs), flash memory, semiconductor components, and memory modules. Their official website is www.micron.com and they are listed on the Nasdaq stock exchange. Their main operations are located in Boise, United States, and they fall under the Information Technology sector, focusing on the Semiconductors & Semiconductor Equipment industry.